Clinical Trial Update: Fuzeon (Enfuvirtide) Early Access Program for Patients With HIV-1 Infection [Phase 3]

View source ↗

Summary

Phase 3 Early Access Program update for Fuzeon (enfuvirtide) in HIV-1 infection; the trial status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Fuzeon (enfuvirtide)

Snippet

Sponsor: National Institute of Allergy and Infectious Diseases (NIAID) | Conditions: HIV Infections | Phase 3 | Status: COMPLETED